FDA Accepts Resubmitted Camrelizumab Rivoceranib Applications

Company Jiangsu Hengrui; Elevar Therapeutics Event Type FDA acceptance of resubmission Modality Anti-PD-1 antibody plus oral TKI Asset Camrelizumab plus rivoceranib Target PD-1; VEGFR2 Disease Area Unresectable or metastatic hepatocellular carcinoma Summary Previously missed November 4 regulatory update, corroborated by a November 5 Chinese exchange…